Search Index

Revolutionising drug discovery Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A breakthrough procedure for efficient and effective development 08/07/25, 14:35 Last updated: Published: 07/01/24, 14:05 Revolutionising drug discovery Discover how researchers have transformed the early stages of drug development with a ground-breaking test that identifies the most promising compounds. "Saving time and resources by focusing on the most potential compounds". Researchers at the Centre for Cancer Drug Discovery at The Institute of Cancer Research (ICR), London have made a significant breakthrough in the field of drug discovery. Their new investigative procedure promises to revolutionize the early stages of drug development by making it more efficient and effective. This ground-breaking test allows scientists to identify new biologically active compounds with the highest potential, saving valuable time and resources. Thanks to this procedure, researchers worldwide can now select only the most promising compounds to develop into effective medications. The study, funded by Cancer Research UK, has been published in the prestigious Journal of Medicinal Chemistry, highlighting its importance and impact on the field. A new approach to fragment-based drug discovery Fragment-based drug discovery has become the standard method for identifying the starting point of a drug discovery program. Scientists screen libraries of compounds, known as fragments, to determine their interaction with a potential anti-cancer target. Previously, scientists could only qualify the interactions between fragments and target proteins as a simple "yes" or "no". However, weak, or nonspecific interactions were challenging to evaluate accurately. Now, thanks to this latest research, researchers have developed a quantitative approach to measure the strength of these interactions. By ranking the fragments based on their interaction strength, research teams can confidently identify the most active compounds to move forward in the drug development process. This additional information allows scientists to refine the selected fragments by optimizing their shape, combining them with other fragments, or both. The result is a more streamlined and efficient drug discovery workflow. Realising the potential of the new procedure Dr. Maggie Liu, the first author of the study and a Senior Scientific Officer at the ICR, expressed confidence that this new procedure will become an integral part of the standard drug discovery workflow. The method is accessible to any team with the right equipment, providing a valuable tool for the wider drug discovery community. The ICR has already started follow-up work on one of the identified fragments using this new test. They plan to utilize this procedure for all future projects, recognizing its potential to accelerate the development of life-saving drugs. Compounds discovered from fragment-based drug discovery (FBDD) and their potential effects FBDD has emerged as an effective strategy in drug discovery, leading to the identification of several compounds with promising potential, including: 1. Vemurafenib: FDA approved in 2011, Vemurafenib has shown efficacy against specific targets, potentially offering treatment options for certain conditions. 2. Venetoclax: Another FBDD-derived drug, Venetoclax, received FDA approval in 2016. It has demonstrated positive outcomes in clinical trials, indicating its potential as a therapeutic agent. 3. Pexidartinib: Approved in 2019, Pexidartinib is a fragment-derived drug that has exhibited promising effects against its intended targets. 4. Erdafitinib: Similarly, Erdafitinib, developed through FBDD, obtained FDA approval in 2019. It has shown potential in clinical trials, highlighting its significance as a therapeutic option. 5. Sotorasib: This compound, approved in 2021, is another example of a fragment-derived drug with potential therapeutic benefits against specific targets. 6. Asciminib: Lastly, Asciminib, also approved in 2021, is a fragment-based drug that has demonstrated efficacy in clinical trials, showcasing its potential as a therapeutic intervention. These compounds represent a fraction of the molecules discovered through FBDD, and their effects vary depending on the specific targets they interact with. Further research and clinical trials are necessary to fully understand the therapeutic potential of these compounds and their broader impact on various diseases and conditions. Testing the R2KD tool Dr. Liu and her team successfully used the R2KD tool to identify new biologically active compounds. This tool utilizes a ligand-observed nuclear magnetic resonance (LONMR) approach, similar to an MRI scanner, to observe fragment interactions. By measuring the transverse relaxation rate (R2) of the fragments, which indicates their speed in the solution, the researchers could determine the fragments' interaction with the target protein. They then applied a new mathematical formulation to calculate a binding affinity value (Kd) for each fragment and compare their Kd values. This allowed them to identify the fragments with the strongest interactions. The researchers named their test 'R2KD'; based on these steps. By using this method, scientists can now quantitatively determine the binding affinity of fragments, which helps in selecting compounds with the most potential for further development. This new procedure makes the early stages of drug discovery more efficient, saving time and resources by focusing on the most promising compounds. Written by Sara Maria Majernikova Related articles: AI in drug discovery / AI in medicinal chemistry / A breakthrough in prostate cancer treatment / Arginine and tumour growth Project Gallery

An extensive collection of insightful reviews on the best STEM books available. Whether you're a student looking to deepen your knowledge or something to aid your revision and research, an educator seeking great resources for your classroom, or simply a curious mind passionate about science, technology, engineering, mathematics, medicine and more, you'll find something here to inspire and inform you.  Discover Your Next Great Read Deep Dive into STEM Books Here you can explore an extensive collection of insightful reviews on the best STEM books available. Whether you're a student looking to deepen your knowledge or something to aid or complement your revision and research, an educator seeking great resources for your classroom, or simply a curious mind passionate about science, technology, engineering, mathematics, medicine and more, you'll find something here to inspire and inform you. Our Curated Selections: Intern Blues by Robert Marion, M.D. The Emperor of All Maladies by Siddhartha Mukherjee The Molecule by Dr Rick Sax and Marta New

Lucy, Betsy, and Anarcha Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The Foremothers of Gynaecology 10/07/25, 10:18 Last updated: Published: 05/03/24, 12:15 Lucy, Betsy, and Anarcha In collaboration with Dr Aakila Sammy from Publett for International Women's Month We have honoured remarkable women in science across the centuries. From Marie Curie's pioneering research on radioactivity in the 1800s to Henrietta Lacks's unintentional contribution to immortalised human cell lines in the 1900s and Rosalind Franklin's crucial work on the structure of DNA. Yet, even as their achievements shine, the names of their male counterparts, like Watson and Crick, often dominate the narrative. Let's journey back a century or two. Were the experiences of Lucy, Betsy, and Anarcha, the foremothers of gynaecology, similar? In the 19th century, Dr. James Marion Sims was celebrated as a surgical hero and the father of gynaecology. His fame stemmed from pioneering the first reliable surgery to treat vesicovaginal fistula, a severe childbirth complication causing a hole between a woman's bladder and vagina, leading to continuous urinary leakage and sometimes palliative care. Sims conducted his initial attempts at a small hospital behind his home in Montgomery, Alabama, focusing on enslaved African American women whom he housed. Over several years, he performed numerous operations on these women. Historical records indicate that 12 enslaved women underwent experimentation, with only three identified by name: Lucy, Betsy, and Anarcha. While Sims did treat white women, indicating a universal need for treatment, he probably began experimenting with black women first. Unfortunately, many records were destroyed after slavery ended, obscuring our understanding of these events. Consequently, many who suffered or displayed bravery may not receive proper historical recognition. But we're about to change that here! Slave owners often viewed enslaved women as valuable assets due to their potential to increase the slave population and, thus, the owner's wealth through labour. However, when complications arose during childbirth, rendering these women unable to work, slave owners sought alternative means to cover medical expenses and maintain profitability. This often involved leasing them to physicians like Sims for medical experimentation and treatment. Additionally, enslaved women who experienced complications during childbirth were often ostracised by their communities and left with no choice but to comply with the demands of their owners. While on lease, these teenage girls aged 17 to 19 worked for the Sims family and were subjected to experimentation, naked and restrained in front of an audience of male doctors. Lucy was the first of the three women to undergo Sims's experimental operation and remained conscious throughout the entire hour-long surgery. Post-surgery, Lucy developed an infection, and even though Sims was able to cure her infection, her injuries did not heal, which rendered the operation a failure. Betsy was operated on next with the same outcome minus the infection. Anarcha, operated on last, had the same results, but this did not stop Sims. Sims persisted in his experiments, even when his male assistants quit. He eventually trained the women to assist each other during surgeries, and over time, they became proficient enough to be considered medical practitioners in their own right. The turning point came after Anarcha's 30th surgery, where success was finally achieved. However, shortly afterwards, Sims closed his hospital and relocated north. The fate of the women after this point is noted as being returned to their masters, indicating the continued exploitation and oppression they faced despite their contributions to medical science. While Sims's legacy indeed sparks ethical concerns about consent, anaesthesia, and racism, it's vital to recognise the dire circumstances faced by the women he treated and their significant contributions to his work. Despite the troubling context of slavery, characterised by ambiguous consent, potential underuse of anaesthesia, and the enduring belief that black women could endure more pain (a misconception that persists in healthcare today), these women sought relief from their suffering. Or was it their slave owners who sought to protect their investment? In addition to recognising the systemic exploitation and dehumanisation suffered by enslaved individuals, it is important to celebrate the resilience and bravery of these women, who played a crucial role in advancing gynaecological understanding and techniques. Now, just a mile from the remaining Sims statue stands another monument honouring the true mothers of gynaecology: Lucy, Betsy, and Anarcha (by the artist and activist Michelle Browder). These teenagers played a profound role in shaping the field. It's imperative that we shift the narrative to acknowledge them as our foremothers in gynaecology when recounting this history. Their names deserve a place in the textbooks as well. -- Scientia News wholeheartedly thanks Aakila Sammy , co-founder and CEO of Publett , for this interesting article on the pioneering individuals in the field of gynaecology. We hope you enjoyed reading this International Women's Month Special piece! Follow them @Dr.Publett on Instagram and @Publett Limited on Linkedin for more information. -- Our last collaboration: Micro-chimerism and George Floyd's death Related articles: Female Nobel prize winners in physics and in chemistry / African-American women in cancer research / Women leading the charge in biomedical engineering / Endometriosis and PCOS / Postpartum depression in adolescent mothers REFERENCES National Library of Medicine. "Vesicovaginal fistula was a catastrophic complication of childbirth for many enslaved women between 1845 and 1849." Accessed 28th February 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2563360/#:~:text=Vesicovaginal%20fistula%20was%20a%20catastrophic,women%20between%201845%20and%201849 . ProQuest. "Anarcha, Betsey, and Lucy: The Mothers of Modern Gynecology."Accessed 28th February 2024. https://www.proquest.com/openview/a02db7be4c84ed0066ed13e79513b6ad/1?pq-origsite=gscholar&cbl=41361 . Smithsonian Magazine. "A monument honouring enslaved women, known as the 'Mothers of Gynecology' has been erected."Accessed 28th February 2024. https://www.smithsonianmag.com/smart-news/mothers-of-gynecology-monument-honors-enslaved-women-180980064/ New York Historical Society. "To learn more about Anarcha, Betsey, and Lucy, visit the New York Historical Society's online exhibit, 'A Nation Divided: The Civil War Era"'.Accessed 28th February 2024. https://wams.nyhistory.org/a-nation-divided/antebellum/anarcha-betsy-lucy/ . Project Gallery

Unlocking the secrets to gut health Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The power of probiotics 10/04/26, 10:51 Last updated: Published: 18/08/23, 19:58 Unlocking the secrets to gut health What are probiotics? Probiotics are dietary supplements that consist of live cultures of bacteria or yeast. In the human body, more precisely in the microbiome, there are about 4 trillion bacteria, which include almost 450 species. These bacteria are necessary for the proper functioning of the entire body, especially the intestines and digestive system. In probiotics, bacteria from the Lactobacillus and Bifidobacterium families are most often used, as well as yeasts such as Saccharomyces cerevisiae. How do probiotics work? Probiotics have a wide range of effects on our body. Their main task is to strengthen immunity and improve the condition of the digestive tract. This is because microorganisms produce natural antibodies, and also constitute a kind of protective barrier that does not allow factors conducive to infection to our intestine. Types of probiotics Most often, lactic acid bacteria of the genera Lactobacillus and Bifidobacterium are used as probiotics, but some species of Escherichia and Bacillus bacteria and the yeast Saccharomyces cerevisiae boulardi also have pro-health properties. Probiotics for your gut health The composition of our bacterial flora in the intestines determines the proper functioning of the digestive and immune systems. Probiotics have a positive effect primarily on the intestinal flora. They speed up metabolism and lower bad cholesterol (LDL). Live cultures of bacteria protect our digestive system. They improve digestion, regulate intestinal peristalsis, and prevent diarrhoea. They also increase the nutritional value of products - they facilitate the absorption of minerals such as magnesium and iron as well as vitamins from group B and K. In addition, probiotics strengthen immunity and protect us from infections caused by pathogenic bacteria. Therefore, it is very important to take as many probiotics as possible during and after antibiotic treatment. They will then regenerate the intestinal flora damaged by antibiotic therapy and reduce inflammation. Main benefits · facilitate the digestive process · increase the absorption of vitamins and minerals · during antibiotic treatments, they protect our intestinal microflora · affect the immune system by increasing resistance to infections · some strains have anti-allergic and anti-cancer properties · lower cholesterol · relieve the symptoms of lactose intolerance · ability to synthesize some B vitamins, vitamin K, folic acid Written by Aleksandra Zurowska Related articles: The gut microbiome / Vitamins / Interplay of hormones and microbiome Project Gallery

A chemical perspective Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The environmental impact of EVs 16/01/25, 11:21 Last updated: Published: 07/08/23, 15:58 A chemical perspective Electric vehicles (EVs) are gaining momentum worldwide as a greener alternative to conventional internal combustion engine vehicles (ICEVs). The environmental benefits of EVs extend beyond their efficient use of electricity. In this article, we explore the chemical aspects of EVs and their environmental impact, shedding light on their potential to mitigate climate change and reduce pollution. Greenhouse Gas Emissions Reduction: EVs play a crucial role in addressing climate change by significantly reducing greenhouse gas (GHG) emissions. Unlike ICEVs that rely on fossil fuels, EVs generate zero tailpipe emissions. By utilising electricity as their energy source, EVs minimise the release of carbon dioxide (CO2) and other GHGs responsible for global warming. However, it's essential to consider the environmental implications of electricity generation, emphasising the need for renewable energy sources to maximise the positive impact of EVs. Battery Chemistry and Resource Management: The heart of an EV lies in its rechargeable battery, typically composed of lithium-ion technology. The production and disposal of these batteries present both opportunities and challenges. Raw materials, such as lithium, cobalt, and nickel, are essential components of EV batteries. Responsible mining practices and efficient recycling techniques are vital to minimising the environmental impact of resource extraction and ensuring proper disposal or repurposing of used batteries. Electrochemical Reactions and Energy Storage: Electric vehicles rely on electrochemical reactions within their batteries to store and release energy. These reactions involve the flow of ions, typically lithium ions, between the positive and negative electrodes. Understanding the chemistry behind these processes enables the development of more efficient and durable battery systems. Continued research and innovation in battery chemistry hold the potential to enhance energy storage capabilities, extend EV range, and improve overall performance. Air Quality and Emission Reduction: EVs contribute to improved air quality due to their zero tailpipe emissions. By eliminating the release of pollutants such as nitrogen oxides (NOx), particulate matter (PM), and volatile organic compounds (VOCs), EVs reduce smog formation and respiratory health risks. This is particularly significant in urban areas, where high concentrations of vehicular emissions contribute to air pollution. The adoption of EVs can help combat these issues and create cleaner and healthier environments. Battery Recycling and the Circular Economy: Given the increasing demand for EVs, battery recycling plays a vital role in ensuring a sustainable future. Recycling allows for the recovery of valuable materials and reduces the need for resource extraction. Effective recycling processes can mitigate the environmental impact of battery production, minimise waste generation, and promote a circular economy approach, where materials are reused and recycled to their fullest extent. Future Prospects and Chemical Innovations : Advancements in battery technology and chemical engineering are key to unlocking the full potential of EVs. Research efforts are focused on developing alternative battery chemistries, such as solid-state batteries, which offer improved energy density, safety, and recyclability. Additionally, exploring sustainable materials and manufacturing processes for batteries can further reduce the environmental footprint of EVs. In conclusion, electric vehicles represent a promising solution to combat climate change, reduce pollution, and promote sustainable transportation. From the chemistry behind battery systems to their impact on air quality and resource management, EVs offer a greener alternative to traditional vehicles. Continued research, innovation, and collaboration between the automotive industry, chemical scientists, and policymakers are essential for realising the full potential of EVs and creating a cleaner, more sustainable future. Written by Navnidhi Sharma Related articles: Hydrogen cars / The brain-climate connection / Plastics and their environmental impact Project Gallery

Insight into the different stages Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link A deep dive into ovarian cancer 03/07/25, 10:24 Last updated: Published: 04/04/24, 14:41 Insight into the different stages Introduction Ovarian cancer occurs when abnormal cells in the ovary begin to grow and divide uncontrollably ; this may lead to tumour formation. According to Cancer Research UK , there are around 7,500 new cases of ovarian cancer each year - that is around 21 a day. This makes ovarian cancer the 6th most common cancer in females in the UK, as it makes up around 4% of all cancer cases. Nevertheless, a total of around 11% of all ovarian cancer cases are thought to be preventable. This article aims to provide a comprehensive overview of ovarian cancer including the risk factors, prevention, diagnosis, and treatment. Diagnostics At present, there is no screening test specific for ovarian cancer. Hence, this often leads to late-stage diagnosis, which results in death or high rates of recurrence within ten years of initial diagnosis, should remission be reached. Initial diagnostic testing includes transvaginal ultrasonography and serum cancer antigen 125 (CA 125) level testing. Transvaginal Ultrasonography This type of imaging is used to assess the overall architecture and vascularity of the ovaries as well as to differentiate cystic from solid masses and detect ascites (a collection of fluid within abdominal spaces). The sensitivity (a tests ability to correctly identify if an individual has a disease) and specificity (a tests ability to correct identify individuals who do not have a disease) for distinguishing malignant lesions using this type of imaging is 86% - 94%. Blood Testing Complete blood count, as well as liver function tests, calcium, and serum biomarkers, are often obtained if ovarian cancer is suspected. CA 125 is the most commonly tested biomarker. However, its usefulness in the diagnosis of ovarian cancer depends on the stage of the disease at the time of testing. CA 125 is elevated in around 80% of epithelial ovarian cancers overall. However, it is only elevated in around 50% of early-stage epithelial ovarian cancers. This biomarker may also rise in conditions such as fibroids and endometriosis. Other biomarkers involved include human epididymis protein 4 (HE4), a glycoprotein expressed in about 1/3rd of ovarian cancers that lack elevated CA125. Biomarkers for non-epithelial cancers include inhibin A/B for sex-cord stromal tumours and serum α-fetoprotein and quantitative human chorionic gonadotropin for germ cell tumours. Staging Ovarian cancer is often categorised using the FIGO (1 – 4 staging) system, named after the International Federation of Gynaecological Oncologists. Stage 1 Stage one ovarian cancer means that the cancer is only located in the ovaries and is further divided into three groups. According to the CRUK website the three groups are: Stage 1A : the cancer is entirely confined within a singular ovary Stage 1B : the cancer is entirely confined within both ovaries Stage 1C is split into 3 subgroups: Stage 1C1 : the cancer is present in one or both ovaries and the ovary ruptures during a surgical procedure Stage 1C2 : the cancer is present in one or both ovaries and the ovary ruptures before a surgical procedure or there is evidence of cancer on the surface of the ovary Stage 1C3 : the cancer is present in one or both ovaries and cancer cells are detected in the fluid collected from the abdominal cavity during surgery These groups can be further illustrated in Figure 1 at the end of the text. Stage 2 Stage 2 ovarian cancer means the cancer has grown outside the ovaries and is growing within the pelvis. It is divided into two groups. According to the CRUK website the two groups are. Stage 2A : the cancer has extended its growth into either the fallopian tubes or the womb Stage 2B : the cancer has infiltrated surrounding tissues within the pelvic region such as the bladder or the bowel These groups can be further illustrated in Figure 2 at the end of the text. Stage 3 Stage 3 ovarian cancer means the cancer has grown outside the pelvis into the abdominal cavity or lymph nodes. It is divided into three groups. According to the CRUK website the three groups are: Stage 3A is divided into two subgroups: Stage 3A1 : the cancer has infiltrated lymph nodes in the rear of the abdomen Stage 3A2 : there are cancer cells detected in tissue samples taken from the peritoneum, cancer may also be present within the lymph nodes Stage 3B : Cancerous growths are present on the peritoneum that measure up to 2 cm in size, cancer may also be present within the lymph nodes Stage 3C : Cancerous growths are present on the peritoneum that measure over 2 cm in size, cancer may also be present within the lymph nodes These groups can be further illustrated in Figure 3 and Figure 4 at the end of the text. Stage 4 Stage 4 ovarian cancer means the cancer has metastatic and has spread to organs some distance away from the ovaries. It is divided into two groups. According to the CRUK website, the two groups are: Stage 4A : the cancer has induced a build-up of fluid in the pleura Stage 4B : the cancer has infiltrated various locations throughout the body including the interior of the liver or spleen, lymph nodes outside the abdominal region and any other organ within the body These groups can be further illustrated in Figure 5 and Figure 6 at the end of the text. Types of Ovarian Cancers There are three known types of ovarian cancer: epithelial, germ cell ovarian tumours and sex cord-stromal tumours. Epithelial Ovarian Cancer Epithelial ovarian cancer is the most common type of cancer. According to Cancer Research UK , about 90% of all ovarian tumours are epithelial. In this type of ovarian cancer, cancer starts in the surface layer covering the ovary. There are four stages of epithelial ovarian cancer - stages 1 to 4. Type Summary High-grade serous tumours ● 90% of all tumour tumours ● 10-year mortality rate of roughly 70% Low-grade serous tumours ● 10% of all tumour types ● Diagnosed at a younger age; better prognosis than high-grade serous tumours Endometrioid carcinomas ● Origins linked to endometriosis ● Good prognosis; mostly diagnosed at an early stage and are low-grade Clear cell carcinomas ● Origins linked to endometriosis ● 10% of epithelial ovarian cancers; rare form ● Often diagnosed in early stages. Late diagnosis has a poor prognosis. Mucinous carcinoma ● Least common form of epithelial ovarian cancer ● Origins linked with metastasis from gastrointestinal tract Table 1. Types of epithelial ovarian cancers. Germ Cell Ovarian Cancers Germ cell ovarian tumours are rare as they make up only 3% of ovarian cancer cases. They have a younger age of diagnosis with the average age being between 10 and 30 years old. Germ cell ovarian tumours can be benign (non-cancerous) or malignant (cancerous) Sex Cord-Stromal Tumours Sex cord-stromal tumours (SCSTs) are rare tumours of the ovary that originate in tissues that support the ovaries, known as the stroma or the sex cords. SCSTs account for around 5% of all ovarian cancer cases and are often diagnosed early. There are three main groups of SCSTs: Pure stromal tumours such as fibromas and thecomas. These are mainly benign. Pure sex cord tumours such as adult and juvenile granulosa cell tumours. These are the most common types of SCSTs and are malignant. Mixed sex cord-stromal tumours such as Sertoli-Leydig cell tumours. These can be either malignant or benign. Symptoms Historically, the signs and symptoms of ovarian cancer are non-specific and vague. The most common presenting symptoms in women are: Swelling or bloating of the abdomen Feel full quickly when eating Unexplained weight loss Pelvic and or abdominal pain or discomfort Unexplained fatigue A frequent need to urinate Changes in bowel habits or IBS symptoms The most common presenting symptom in children and adolescents is persistent abdominal pain. However, precocious puberty, irregular periods or hirsutism (excessive hair growth) may also be present. Due to the non-specific nature of these symptoms, many women will not get them checked by a doctor. It is still vitally important for a person to get any non-typical symptoms checked out by a doctor. Early diagnosis will lead to better outcomes. Treatment There are a variety of different treatment options for ovarian cancer. The treatment an individual undergoes is dependent on the size and location of the cancer as well as if it is metastatic. Debulking Surgery Debulking is a type of cytoreductive surgery that aims to remove as much cancer as possible if it has spread to areas within the pelvis and abdomen. This type of surgery is a mainstay of ovarian cancer treatment as most cases are more advanced in staging when initially diagnosed. Generally, debulking surgery is used on cancer that has spread widely throughout the abdomen and its goal is to do ‘optimal cytoreduction’, meaning no visible cancer is left behind or, if removing all visible disease is not possible, lesions less than 1cm in size are left. Hysterectomy For most women, a hysterectomy is the first-line treatment for ovarian cancer. The surgery removes the womb (including the cervix) as well as both ovaries and fallopian tubes and is known as a total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy (BSO) . This procedure is further illustrated by Figure 7 at the end of the text. Chemotherapy Chemotherapy is the use of anti-cancer drugs to destroy cancer. These drugs circulate throughout the body via the bloodstream. In the treatment of ovarian cancer, chemotherapy can be given before, during or after surgery. The most commonly used drugs are carboplatin and paclitaxel. However, these are not the only options. Chemotherapy is typically used in the treatment of ovarian cancer if the cancer is: ● Stage 1C or above ● Stage 1A or 1B but is high grade ● Has come back (recurrence) Medication Route of administration Stage treated Duration Paclitaxel and carboplatin Intravenous I 21 days Paclitaxel and carboplatin Intravenous I 7 days Docetaxel and carboplatin Intravenous I 21 days Paclitaxel and cisplatin Intravenous or intraperitoneal II, III, IV 21 days Paclitaxel and carboplatin Intravenous or intraperitoneal II, III, IV 21 days Dose-dense paclitaxel and carboplatin Intravenous II, III, IV 21 days Paclitaxel and carboplatin Intravenous II, III, IV 7 days Docetaxel and carboplatin Intravenous II, III, IV 21 days Carboplatin and liposomal doxorubicin Intravenous II, III, IV 28 days Bevacizumab with paclitaxel and carboplatin Intravenous II, III, IV 21 days Table 2. Commonly used chemotherapy drugs for ovarian cancer Radiotherapy Radiotherapy involves the use of high-energy X-rays to destroy ovarian cancer cells. It is not the main treatment of ovarian cancer and is often used to try and shrink the size of tumours or to reduce the symptoms of advanced ovarian cancer. This is known as palliative radiotherapy . Targeted Therapies Cancer-targeting drugs change how a cell works by acting on cellular processes or by modifying cell signalling. They stimulate the body to attack or control cancer cell growth. These drugs are a form of palliative treatment. The two most common drugs are olaparib and bevacizumab. Olparib Olaparib (Lynparza) belongs to a drug type known as cancer growth blockers. It acts on PARP (poly ADP-ribose polymerase); a protein that helps damaged cells repair and regenerate themselves. Olaparib inhibits PARP from working. Bevacizumab Bevacizumab (Avastin) belongs to a drug type known as anti-angiogenesis treatments. It targets VEGF (vascular endothelial growth factor) proteins. VEGFs aid in cancer cell growth as they help cancers develop their blood supplies, meaning they can become self-sufficient. Bevacizumab blocks VEGF proteins from working, which cuts off the blood supply that feeds the cancer, ultimately starving it and preventing its growth. Risk Factors Modifiable Nonmodifiable Smoking BRCA1 and/ord BRCA2 mutation carrier Hormone Replacement Therapy (particularly for more than five years) Family predisposition/history Obesity Lynch syndrome Endometriosis Uninterrupted ovulation cycles Ethnicity/race Table 3. Ovarian cancer risk factors Genetic Syndromes Familial genetic syndromes are the strongest known risk factor for the development of ovarian cancers, as they account for around 10% - 12% of all cases. Table 4 which is taken from the paper ‘Diagnosis and Management of Ovarian Cancer’ by Doubeni et al (2016) illustrates genetic syndromes known to have an increased risk of ovarian cancer. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) Mutations of the BRCA1 and BRCA2 genes are primarily associated with a genetic risk of developing ovarian cancer and can increase the risk from 1.6% to 40% ( BRCA1 ) and 1.6% to 18% ( BRCA2 ). This syndrome should be considered if a woman has close blood relative with a diagnosis of ovarian or breast cancer by the age of 50. Lynch Syndrome Although less common, Lynch syndrome is also linked to the development of ovarian cancer as it is involved in 2% - 3% of cases. Lynch syndrome is an autosomal dominant genetic disorder in which there is a mutation that increases the risk for certain cancers, specifically colorectal cancer, as well as increases the risk for other malignancies. Ovulation Ovulation is directly linked to the risk of ovarian cancer. Studies have shown that the more ovulatory cycles a woman has, the higher her risk of developing ovarian cancer. This may be due to the pro-inflammatory response from the distal fallopian tube during ovulation, which is known to promote malignant ovarian tendencies. Assuming this is true, factors that interrupt or prevent ovulation, such as contraception, early onset menses, pregnancy, breastfeeding and early menopause, could decrease a woman’s risk of developing ovarian cancer. Endometriosis Endometriosis, a disease in which tissue similar to the uterine lining grows outside the uterus, is known to be linked to some types of epithelial ovarian cancers. Endometriosis-associated epithelial ovarian cancers tend to develop in younger women and have an overall better prognosis. -- Where to seek help if affected by this article... F or support and more information regarding ovarian cancer: Macmillan Cancer Research If you or somebody you know have been affected by this article, help is always available: Mind and Samaritans -- Written by Lily Manns Related articles: A breakthrough drug discovery process in cancer treatment / Immune signals and metastasis / Novel neuroblastoma driver for therapeutics Reference guide Cancer Research. Ovarian Cancer Statistics: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-c ancer Cancer Research. Epithelial Ovarian Cancer: https://about-cancer.cancerresearchuk.org/about-cancer/ovarian-cancer/types/epithelial-ovarian-cancers/ep ithelial Cancer Research. Stages and grades of ovarian cancer: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/stages-grades Elsevier. Ovarian Cancer: An integrated review: https://www.sciencedirect.com/science/article/pii/S0749208119300129?via%3Dihub American Family Physician. Diagnosis and Management of Ovarian Cancer: https://www.aafp.org/pubs/afp/issues/2016/0601/p937.html Cancer Research. Treatment for Ovarian Cancer: https://www.cancerresearchuk.org/about-cancer/ovarian-cancer/treatment Project Gallery

Understanding the problem and solutions Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The rising threat of antibiotic resistance 14/07/25, 15:00 Last updated: Published: 07/01/24, 13:47 Understanding the problem and solutions An overview and history of antibiotics Antibiotics are medicines that treat and prevent bacterial infections (such as skin infections, respiratory infections and more). Antibiotic resistance is the process of infection-causing bacteria becoming resistant to antibiotics. As the World Health Organisation (WHO) stated, antibiotic resistance is one of the biggest threats to global health, food security and development. In 1910, Paul Ehrlich discovered the first antibiotic, Salvarsan, used to treat syphilis at the time. His idea was to create anti-infective medication, and Salvarsan was successful. The golden age of antibiotic discovery began with the accidental discovery of penicillin by Alexander Fleming in 1928. He noticed that mould had contaminated one of the petri dishes of Staphylococcus bacteria. He observed that bacteria around the mould were dying and realised that the mould, Penicillium notatum , was causing the bacteria to die. In 1940, Howard Florey and Ernst Chain isolated penicillin and began clinical trials, showing that it effectively treated infectious animals. Penicillin was then used to treat patients by 1943 in the United States. Overall, the discovery and use of antibiotics in the 21st century was a significant scientific discovery, extending people’s lives by around 20 years. Factors contributing to antibiotic resistance Increasing levels of antibiotic resistance could mean routine surgeries and cancer treatments (which can weaken the body’s ability to respond to infections) might become too risky, and minor illnesses and injuries could become more challenging to treat. There are various factors contributing to this, including overusing and misusing antibiotics and low investment in new antibiotic research. Antibiotics are overused and misused due to misunderstanding when and how to use them. As a result, antibiotics may be used for viral infections, and an entire course may not be completed if patients start to feel better. Some patients may also use antibiotics not prescribed to them, such as those of family and friends. Moreover, there has not been enough investment to fund the research of novel antibiotics. This has resulted in a shortage of antibiotics available to treat infections that have become resistant. Therefore, more investment and research are needed to prevent antibiotic resistance from becoming a public health crisis. Combatting antibiotic resistance One of the most effective ways to combat antibiotic resistance is through raising public awareness. Children and adults can learn about when and how to use antibiotics safely. Several resources are available to help individuals and members of the public to do this. Some resources are linked below: 1. The WHO has provided a factsheet with essential information on antibiotic resistance. 2. The Antibiotic Guardian website is a platform with information and resources to help combat antibiotic resistance. It is a UK-wide campaign to improve and reduce antibiotic prescribing and use. Visit the website to learn more, and commit to a pledge to play your part in helping to solve this problem. 3. Public Health England has created resources to support Antibiotic Guardian. 4. The E-bug peer-education package is a platform that aims to educate individuals and provide them with tools to educate others. Written by Naoshin Haque Related articles: Anti-fungal resistance / Why bacteria are essential to human survival Project Gallery

Julius Oppenheimer Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The chemistry of an atomic bomb 04/07/25, 12:57 Last updated: Published: 23/08/23, 16:29 Julius Oppenheimer Julius Robert Oppenheimer, often credited with leading the development of the atomic bomb, played a significant role in its creation in the early 1940s. However, it is essential to recognise the collaborative effort of many scientists, engineers, and researchers who contributed to the project. The history and chemistry of the atomic bomb are indeed fascinating, shedding light on the scientific advancements that made it possible. The destructive power of an atomic bomb stems from the rapid release of energy resulting from the splitting, or fission, of fissile atomic nuclei in its core. Isotopes such as uranium-235 and plutonium-239 are selected for their ability to undergo fission readily and sustain a self-sustaining chain reaction, leading to the release of an immense amount of energy. The critical mass of fissionable material required for detonation ensures that the neutrons produced during fission have a high probability of impacting other nuclei and initiating a chain reaction. To facilitate a controlled release of energy, neutron moderation plays a crucial role in the functioning of an atomic bomb. Neutrons emitted during fission have high velocities, making them less likely to be absorbed by other fissile material. However, by employing a moderator material such as heavy water (deuterium oxide) or graphite, these high-speed neutrons can be slowed down. Slowing down the neutrons increases the likelihood of their absorption by fissile material, enhancing the efficiency of the chain reaction and the release of energy. The sheer magnitude of the energy released by atomic bombs is staggering. For example, one kilogram (2.2 pounds) of uranium-235 can undergo complete fission, producing an amount of energy equivalent to that released by 17,000 tons (17 kilotons) of TNT. This tremendous release of energy underscores the immense destructive potential of atomic weapons. It is essential to note that the development of the atomic bomb represents a confluence of scientific knowledge and technological advancements, with nuclear chemistry serving as a foundational principle. The understanding of nuclear fission, the critical mass requirement, and the implosion design were key factors in the creation of the atomic bomb. Exploring the chemistry behind this devastating weapon not only provides insights into the destructive capabilities of atomic energy but also emphasises the responsibility that accompanies its use. In conclusion, while Oppenheimer's contributions to the development of the atomic bomb are significant, it is crucial to acknowledge the collective effort that led to its creation. The chemistry behind atomic bombs, from the selection of fissile isotopes to neutron moderation, plays a pivotal role in harnessing the destructive power of nuclear fission. Understanding the chemistry of atomic weapons highlights the remarkable scientific achievements and reinforces the need for responsible use of atomic energy. Written by Navnidhi Sharma Project Gallery

From foe to ally Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Herpes vs devastating skin disease 09/07/25, 14:16 Last updated: Published: 06/01/24, 11:14 From foe to ally This is article no. 3 in a series on rare diseases. Next article: Epitheliod hemangioendothelioma . Previous article: Breast cancer in males . Have you ever plucked loose skin near your nail, ripping off a tiny strip of good skin too? Albeit very small, that wound can be painful. Now imagine that it is not just a little strip that peels off, but an entire sheet. And it does not detach only when pulled, but at the slightest touch. Even a hug opens wounds, even a caress brings you pain. This is life with recessive dystrophic epidermolysis bullosa (RDEB), the most severe form of dystrophic pidermolysis bullosa (DEB). Herpes becomes a therapy DEB is a rare genetic disease of the skin that affects 3 to 10 individuals per million people (prevalence is hard to nail down for rare diseases). A cure is still far off, but there is good news for patients. Last May, the US Food and Drug Administration (FDA) approved Vyjuvek (beremagen geperparvec) to treat skin wounds in DEB. Clinical studies showed that it speeds up healing and reduces pain. Vyjuvek is the first gene therapy for DEB. It is manufactured by Krystal Biotech and - get this- it is a tweaked version of the herpes virus. Yes, you got that right, the virus causing blisters and scabs has become the primary ally against a devastating skin disease. This approval is a milestone for gene therapies, as Vyjuvek is the first gene therapy - based on the herpes virus, - to apply on the skin as a gel, - approved for repeated use. This article describes how DEB, and especially RDEB, affects the skin and wreaks havoc on the body; the following article will explain how Vyjuvek works. DEB disrupts skin integrity We carry around six to nine pounds of skin. Yet we often forget its importance: it stops germs and UVs, softens blows, regulates body temperature and makes us sensitive to touch. Diseases that compromise the skin are therefore devastating. These essential functions rely on the organisation of the skin in three layers: epidermis, dermis and hypodermis ( Figure 1 ). Typically, a Velcro strap of the protein collagen VII firmly anchors the epidermis to the dermis. The gene COL7A1 contains the instructions on how to produce collagen VII. In DEB, mutations in COL7A1 result in the production of a faulty collagen VII. As the Velcro strap is weakened, the epidermis becomes loosely attached to the dermis. Mutations in one copy of COL7A1 cause the dominant form of the disease (DDEB), mutations in both copies cause RDEB. With one copy of the gene still functional, the skin still produces some collagen VII, when both copies are mutated, little to no collagen VII is left. Therefore, RDEB is more severe than DDEB. In people with RDEB, the skin can slide off at the slightest touch and even gentle rubs can cause blisters and tears ( Figure 2 ). Living with RDEB Life with RDEB is gruelling and life expectancy doesn't exceed 30 years old. Wounds are very painful, slow to heal and get infected easily. The risk of developing an aggressive skin cancer is higher. The constant scarring can cause limb deformities. In addition, blisters can appear in the mouth, oesophagus, eyes and other organs. There is no cure for DEB for now; treatments can only improve the quality of life. Careful dressing of wounds promotes healing and prevents infections. Painkillers are used to ease pain. Special diets are required. And, to no one's surprise, physical activities must be avoided. Treating RDEB Over the past decade, cell and genetic engineering advances have sparked the search for a cure. Scientists have explored two main alternatives to restore the production of collagen VII in the skin. The first approach is based on transferring skin cells able to produce collagen VII. Despite promising results, this approach treats only tinyl patches of skin, requires treatments in highly specialised centres and it may cause cancer. The second approach is the one Vyjuvek followed. Scientists place the genetic information to make collagen VII in a modified virus and apply it to a wound. There, the virus infects skin cells, providing them with a new COL7A1 gene to use. These cells now produce a functional collagen VII and can patch the damage up. We already know which approach came up on top. Vyjuvek speeds up the healing of wounds as big as a smartphone. Professionals can apply it in hospitals, clinics or even at the patient’s home. And it uses a technology that does not cause cancer. But how does Vyjuvek work? And why did scientists choose the herpes virus to build Vyjuvek? We will find the answer in the following article. And since perfection does not belong to biology, we will also discuss the limitations of this remarkable gene therapy. NOTES: 1. DEB is part of a group of four inherited conditions, collectively named epidermolysis bullosa (EB), where the skin loses integrity. EB is also known as “Butterfly syndrome” because the skin becomes as fragile as a butterfly’s wing. These conditions are EB simplex, junction EB, dystrophic EB and Kindler EB. 2. Most gene therapies are based on modified, or recombinant in science jargon, adenoassociated viruses, which I reviewed for Scientia News. 3. Over 700 mutations have been reported. They disrupt collagen VII and its function with various degrees of severity. Consequently, RDEB and DDEB display several clinical phenotypes. 4. Two studies have adopted this approach: in the first study, Siprashvili and colleagues (2016) grafted ex vivo retrovirally-modified keratinocytes, the main cell type in the epidermis, over the skin of people with RDEB; in the second study, Lwin and colleagues (2019) injected ex vivo lentivirally-modified fibroblasts in the dermis of people with RDEB. Written by Matteo Cortese, PhD Related article: Ehlers-Danlos syndrome Project Gallery

The true cost Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Turkey Teeth 04/04/26, 15:32 Last updated: Published: 26/11/23, 10:57 The true cost Coined as 'Turkey teeth,' the rising trend of dental tourism has gained increasing popularity among the British population, largely influenced by social media. Many people are now traveling abroad for veneers, crowns, and implants, in the hope of achieving the perfect smile at a fraction of the cost in the UK. However, patients may be paying with their future oral health in the long run, as evidence emerges of botched procedures, with crucial steps missed and patients having long-lasting pain following their treatment. Many young people opt to visit cosmetic dentistry clinics in European countries to obtain veneers due to their cheaper costs compared to the UK dental fees, given that cosmetic dentistry is not covered under the subsidised NHS prices. However, it is becoming increasingly apparent that many consumers are in fact receiving full dental crowns without their knowledge, as opposed to veneers, thus sacrificing more of their natural tooth structure in the trade for a seemingly perfect smile. A critical difference between crowns and veneers is the amount of natural tooth structure removed to fit the prosthesis. Veneers are a much more minimally invasive fix, whereby 0.5mm of enamel is shaved away to allow a porcelain cover to fit to the surface of the tooth. Veneers are primarily used to conceal enamel discoloration, variations in shades, and natural tooth shapes. The minimally invasive procedure preserves tooth tissue and can even be potentially reversible in cases where there has been no preparation to the tooth. Crowns in the UK are vastly indicated for badly broken-down teeth and teeth deemed unrestorable. The preparation for a crown is far more invasive, with a significant amount of tooth structure irreversibly removed. This process sees teeth shaved down, with almost 2mm of the structure being irreversibly removed. Filing down teeth when they are otherwise perfectly clinically healthy can have dire consequences, and many patients returning to England have found themselves needing corrective work to rectify the procedures they underwent abroad. A study conducted by the Irish Dental Association revealed that 75% of those who travelled abroad for dental procedures required corrective work back home. The harsh reality of this treatment is that it can result in severe infections, long-lasting tooth pain, inflamed gums, exposed nerves, and heightened sensitivity. The destructive process of crown preparations in clinically healthy teeth increases the likelihood of exposing the tooth's pulp as more tooth tissue is removed, making the tooth more susceptible to infection. If the tooth's pulp becomes exposed, a costly and uncomfortable root canal procedure may be necessary. In the long term, these patients are more likely to lose the affected teeth altogether, as irreversible damage has occurred to the teeth. Another disadvantage of quick-fix dentistry abroad is the lack of follow-up appointments. In the UK, services such as occlusion checks are offered to ensure the bite is correct and that the veneers provide the desired result while lasting for an extended period. In contrast, dental procedures abroad are often expedited, sometimes limited to a single appointment as tourists return home swiftly to resume their daily lives. This can raise the risk of rushed procedures and a lack of follow-up to ensure the prosthetics' longevity. This has seen patients crowns falling off, and leaving their teeth exposed. In a typical UK dental clinic, the process involves an initial assessment, a dental health check, trial designs, and finally, the fitting of new veneers. Teeth are meticulously assessed for potential issues, including periodontal disease, and bite evaluations are performed to ensure that the prosthetics do not interfere with the occlusion. This comprehensive approach differs significantly from the one-appointment dentistry often observed abroad. Love Island's Jack Finham underwent the procedure and documented his experience across social media to thousands of followers. He later went on to reveal that in hindsight, he would not have chosen the procedure has he known its intricacies. Influencers are slowly turning to reveal the true costs of fast dentistry abroad, and it can only be hoped that consumers become better informed on the processes performed abroad, and are more well informed before making an irreversible decision for their teeth. In conclusion, it is imperative for consumers to be well-informed when considering dental procedures, especially when faced with the allure of cheaper veneers, or rather crowns abroad. While the cost savings may initially seem enticing, the potential risks associated with overseas treatments, including inadequate follow-ups, irreversible damage to natural tooth structure, and a lack of comprehensive assessments, should not be overlooked. Opting for dentistry in the UK provides a safer and more comprehensive approach, with qualified professionals who prioritise patients' oral health and long-term well-being. While affordability is a significant consideration, the adage "you get what you pay for" holds true in the realm of dental care. Informed decision-making and prioritising one's health should always take precedence when seeking dental treatments, ensuring not only a beautiful smile but also lasting oral health. Written by Isha Parmar Project Gallery